Rapport Therapeutics, Inc. Common Stock
- Open
- 41.40
- Day high
- 41.99
- Day low
- 39.54
- Prev close
- 41.67
- Volume
- 166K
- Mkt cap
- $1.9B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 4.1
- P/S
- 95.5
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$35.9M over the last 3 months (0 open-market buys, 10 sales)
- 🏛Institutions accumulating (13F)
Rapport Therapeutics, Inc. Common Stock (RAPP) is a Healthcare company listed on NASDAQ. The stock is up 268% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 10 sales (SEC Form 4).
Rapport Therapeutics, Inc. Common Stock (RAPP) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
RAPP earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.56 | $-0.42 | +25.0% | $20M | +166.7% |
| Mar 10, 2026 | $-0.65 | $-0.72 | -10.6% | — | — |
| Nov 6, 2025 | $-0.77 | $-0.71 | +7.8% | — | — |
| Aug 7, 2025 | $-0.87 | $-0.75 | +13.8% | — | — |
| May 8, 2025 | $-0.77 | $-0.68 | +11.7% | — | — |
| Mar 11, 2025 | $-0.62 | $-0.57 | +8.1% | — | — |
| Nov 7, 2024 | $-0.57 | $-0.50 | +12.3% | — | — |
| Aug 8, 2024 | $-0.68 | $-1.70 | -150.0% | — | — |
| Mar 30, 2024 | — | $-0.12 | — | — | — |
| Sep 30, 2023 | — | $-0.05 | — | — | — |
RAPP insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 10, 2026 | PAUL STEVEN Mdirector | Grant | 15,200 | $35.21 |
| Jun 10, 2026 | PEREZ ROBERT Jdirector | Grant | 15,200 | $35.21 |
| Jun 10, 2026 | MARAGANORE JOHNdirector | Grant | 15,200 | $35.21 |
| Jun 10, 2026 | Sanchez Ramirodirector | Grant | 15,200 | $35.21 |
| Jun 10, 2026 | Young Wendy B.director | Grant | 15,200 | $35.21 |
| Jun 10, 2026 | Huber Reid Mdirector | Grant | 15,200 | $35.21 |
| Jun 10, 2026 | HEALY JAMESdirector | Grant | 15,200 | $35.21 |
| Jun 10, 2026 | Silva Paul Mdirector | Grant | 15,200 | $35.21 |
| May 28, 2026 | Third Rock Ventures V, L.P.10 percent owner | Sell | 18,572 | $40.05 |
| May 13, 2026 | Third Rock Ventures V, L.P.10 percent owner | Sell | 133,618 | $40.24 |
| May 11, 2026 | Third Rock Ventures V, L.P.10 percent owner | Sell | 5,018 | $40.31 |
| May 11, 2026 | Third Rock Ventures V, L.P.10 percent owner | Sell | 271,495 | $40.12 |
| Apr 21, 2026 | Third Rock Ventures V, L.P.10 percent owner | Sell | 426,005 | $40.32 |
| Apr 21, 2026 | Yeleswaram Krishnaswamyofficer: Chief Development Officer | Sell | 20,225 | $39.99 |
| Apr 14, 2026 | Yeleswaram Krishnaswamyofficer: Chief Development Officer | Sell | 9,165 | $34.97 |
Source: RAPP SEC Form 4 filings, latest Jun 10, 2026. For informational purposes only — not investment advice.
See the full RAPP insider & 13F page →Rapport Therapeutics, Inc. Common Stock company profile
Overview
Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Boston, Massachusetts. The company was originally incorporated as Precision Neuroscience NewCo, Inc. before changing its name in October 2022. Rapport focuses on discovering and developing small molecule medicines to treat central nervous system disorders, representing a relatively young entrant in the competitive biotechnology sector with a specialized focus on neurological conditions.
Business
Rapport Therapeutics operates in the biotechnology industry, specifically targeting central nervous system (CNS) disorders through small molecule drug development. The central nervous system encompasses the brain and spinal cord, and disorders affecting these areas include conditions like epilepsy, chronic pain, bipolar disorder, and hearing impairments. Small molecule drugs are typically chemically synthesized compounds that can cross biological barriers more easily than larger biological drugs, making them particularly suitable for treating brain-related conditions. The company's primary focus centers on three main therapeutic areas. First, their lead program targets focal epilepsy and other CNS disorders through RAP-219, an investigational drug designed to inhibit specific receptors called TARPγ8-containing AMPARs with extremely high precision (picomolar affinity). AMPAR receptors are critical components in brain cell communication, and their malfunction contributes to seizure activity in epilepsy patients. Second, they are developing RAP-199, another TARPγ8-targeted molecule with different chemical properties that may offer advantages in treating peripheral neuropathic pain and bipolar disorder. Third, the company has nicotinic acetylcholine receptor programs focusing on α6 nAChR for chronic pain treatment and α9α10 nAChR for hearing disorders. These receptors are involved in nerve signal transmission and represent novel targets for treating pain and auditory conditions. As a clinical-stage company, Rapport generates no commercial revenue currently, with all resources dedicated to research and development activities across these three therapeutic platforms.
Revenue model
Rapport Therapeutics currently generates no revenue as it remains in the pre-commercial research and development phase. Like most biotechnology companies at this stage, the business model revolves around advancing drug candidates through clinical trials with the ultimate goal of obtaining regulatory approval and commercializing successful treatments. The company's future revenue streams would likely come from product sales of approved medications, potential licensing agreements with larger pharmaceutical companies, and possible partnership deals for co-development or commercialization rights. The paying customers in Rapport's target markets would primarily be healthcare systems, hospitals, neurologists, pain management specialists, and ultimately patients with CNS disorders who require specialized treatments. The epilepsy market alone represents a significant opportunity, as current treatments often provide inadequate seizure control for many patients, creating demand for more effective therapies. Several factors could significantly impact the company's future profitability margins. Regulatory approval success rates represent the most critical factor, as failed clinical trials can eliminate entire revenue streams while successful approvals can generate substantial returns. Clinical trial costs and timelines directly affect cash burn rates and time to potential revenue generation. Competition from established pharmaceutical companies and other biotechnology firms developing similar treatments could limit market share and pricing power. Healthcare reimbursement policies and insurance coverage decisions will determine accessible patient populations and achievable pricing levels. Additionally, manufacturing scale-up costs and the complexity of producing small molecule drugs at commercial quantities will influence gross margins once products reach market.
Competitive moat
Rapport Therapeutics operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages at this early stage. The company's primary potential moat lies in its specialized expertise in TARPγ8-containing AMPAR inhibition, a relatively novel therapeutic approach that could provide first-mover advantages if successful. Their picomolar affinity binding represents highly precise targeting that may differentiate their approach from existing epilepsy treatments. However, this moat remains largely unproven and faces significant challenges. Intellectual property protection through patents provides some defensive positioning, but patent exclusivity periods are limited and competitors can often develop alternative approaches targeting similar pathways. The company's small size and limited resources compared to major pharmaceutical companies create vulnerability to being outpaced by better-funded competitors pursuing similar targets. The biotechnology sector's fundamental challenge is that scientific breakthroughs are difficult to defend long-term, as other companies can develop alternative compounds or approaches once proof-of-concept is established. Large pharmaceutical companies possess substantially greater resources for parallel development programs and can potentially acquire promising smaller competitors. Additionally, regulatory approval requirements mean that even superior science doesn't guarantee commercial success, as clinical trials carry inherent risks regardless of a company's technological advantages. Rapport's competitive position will ultimately depend on execution speed, clinical trial success rates, and the ability to establish strong intellectual property portfolios before larger competitors enter their specific therapeutic niches. The company currently lacks the established market presence, diversified pipeline, or proven commercial capabilities that characterize stronger competitive positions in biotechnology.
Risks & safety
Rapport Therapeutics presents a mixed margin of safety profile typical of early-stage biotechnology companies, with strong liquidity but high cash burn and speculative valuation metrics. • Liquidity position: Strong current ratio of 31.0x and quick ratio of 31.0x indicate excellent short-term financial stability with $57.6 million in cash and short-term investments against minimal current liabilities of $9.4 million. • Cash burn and runway: Quarterly operating cash flow burn of approximately $20.2 million suggests roughly 7-8 quarters of runway at current spending levels, providing reasonable time to advance clinical programs or raise additional capital. • Debt levels: Minimal debt burden with debt-to-equity ratio of only 0.027, eliminating solvency risk from leverage and providing financial flexibility. • Valuation concerns: Price-to-book ratio of 12.4x appears elevated for a pre-revenue company, though this reflects the premium typically assigned to biotechnology companies with promising pipelines. • Operational losses: Significant negative EBITDA of -$27.1 million quarterly and negative return on equity of -8.4% reflect the expected cash consumption during clinical development phases. • Graham net-net ratio: At 0.76, the company trades below its liquidation value, suggesting potential downside protection despite speculative nature.
Recent development
Based on the available financial data, Rapport Therapeutics has demonstrated consistent progress in advancing its clinical pipeline since its 2022 incorporation. The company successfully completed what appears to be a significant financing round, evidenced by the substantial increase in total assets from $31.6 million in 2022 to $314.9 million by the end of 2024. This capital infusion has enabled accelerated research and development activities, reflected in the increasing operational cash burn from $3.2 million in 2022 to over $20 million quarterly by 2025. The company's strategic focus has remained consistent across its three main therapeutic platforms: TARPγ8-targeted treatments for epilepsy and CNS disorders, and nicotinic acetylcholine receptor programs for pain and hearing disorders. The escalating research and development expenses suggest active clinical trial advancement, particularly for their lead candidate RAP-219. The maintenance of a strong balance sheet with minimal debt indicates management's focus on preserving financial flexibility to fund clinical operations through multiple development milestones. Recent quarters show stabilizing cash burn rates, suggesting the company may be reaching more predictable clinical trial execution phases. The preservation of substantial cash reserves while maintaining aggressive development timelines indicates strategic preparation for potential partnership discussions or additional clinical program expansions as key data readouts approach.
RAPP company profile · for informational purposes only — not investment advice.
Track RAPP with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free